Immediate Impact
1 from Science/Nature 62 standout
Citing Papers
GPCR drug discovery: new agents, targets and indications
2025 Standout
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Works of Katherine R. Schultz being referenced
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer
2017
Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer
2016
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Katherine R. Schultz | 449 | 352 | 165 | 8 | 497 | |
| Anna Squadrilli | 387 | 388 | 218 | 17 | 552 | |
| Minhao Fan | 265 | 304 | 174 | 11 | 526 | |
| Angel R. Garcia | 373 | 301 | 248 | 5 | 483 | |
| Vlatka Smoljanović | 483 | 392 | 117 | 19 | 544 | |
| M.P. López-Cabrerizo | 408 | 399 | 145 | 8 | 569 | |
| Shuhang Wang | 367 | 323 | 250 | 8 | 529 | |
| J. Zugazagoitia | 367 | 282 | 216 | 5 | 509 | |
| Hillary E. Mulvey | 376 | 296 | 254 | 9 | 512 | |
| Takashi Nakaoku | 374 | 292 | 242 | 13 | 562 | |
| Amanda C. Pawlak | 417 | 335 | 179 | 5 | 561 |
All Works
Loading papers...